The EU's Falsified Medicines Directive and APIs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The EU's Falsified Medicines Directive and APIs
Siegfried Schmitt, a principal consultant with PAREXEL, discusses how the EU's Falsified Medicines Directive will affect US API production.

Pharmaceutical Technology
Volume 37, Issue 2

Q. The European Commission (EC) has published The Falsified Medicines Directive (Directive 2011/62/EU). What elements are covered by this directive and how does it affect the pharmaceutical industry?


Siegfried Schmitt
A.This directive covers three items, namely safety features (common logo provisions), Internet supply of medicines, and quality of imported APIs. There are differing timelines for these elements to become effective. The first one is the provision on imported APIs, which comes into effect July 1, 2013. The directive applies to any imported active ingredient.

Q. Is it sufficient to assure that the API was manufactured to GMPs (e.g., in accordance with 21 CFR Parts 210 and 211)?

A. Unfortunately, no. The new prerequisite is that the API must have been manufactured in accordance with GMP that is equivalent to that of the European Union. Such proof requires either a GMP certificate from an EU National Competent Authority (NCA), a "conformity of equivalence" statement from the authority of the non-EU country, or a positive assessment (white-listing) by the EC that the non-EU country's regulatory framework provides equivalent assurance of compliance.

Q. The EU already has mutual recognition agreements in place and is a member of the Pharmaceutical Inspection Co-Operation Scheme (PIC/S). Will these countries be automatically on the white list?

A. No. Non-EU countries must actively apply for an assessment by the EC before they can be added to the white list. Alternatively, these countries could issue a certificate of equivalence. The issue with such a certificate is, however, that its acceptability by the European authorities is uncertain.

The vast majority of APIs imported into the EU originate in China, India, USA, Japan, and Switzerland. So far, only Switzerland is on the white list; Japan is considering applying for white-listing; India considers issuing certificates; China's activities are as yet unclear; and the US FDA has not started considering their options.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here